Value
6.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 6.0 |
REPL · Why this verdict
Why Replimune Group (REPL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Replimune combines a bullish analyst-cluster catalyst with a name that has already run past its target, sub-floor quality, cash burn, and extremely high short interest, leaving a binary clinical outcome as the main swing factor for the stock.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A recent cluster of 9 analyst actions detected in the news triggered a bullish news-boost gate, signaling meaningful sell-side attention to a near-term catalyst even as the broader engine remains cautious on the stock. Engine gate (passed) | The analyst cluster should translate into upgraded price targets or coverage initiations that support the stock over the next few months. | →Stable |
| CounterA cluster of analyst notes can just as easily reflect a wave of downgrades or cautious initiations tied to bad news, not necessarily a bullish catalyst. | ||
Replimune's quality score sits below the engine's floor, driven by negative free cash flow and no competitive moat, meaning the investment case rests entirely on clinical catalysts rather than current fundamentals. Quality breakdown | Cash burn should not accelerate and the company should maintain sufficient runway through its next major clinical readout. | →Stable |
| CounterPersistent cash burn without a moat increases the odds of a dilutive capital raise if a clinical setback occurs, which would impair per-share value regardless of the science. | ||
The V9 momentum gate failed (3.8 versus the 4.5 threshold) even as RSI reads overbought at 79, an inconsistency suggesting the recent bounce lacks the broader technical support (falling on-balance volume) needed to sustain a rally. Engine gate (failed) | Momentum should either clear the 4.5 threshold on renewed volume accumulation or the RSI-driven bounce should fade without new highs. | →Stable |
| CounterMomentum gates calibrated for typical equities may not translate well to binary biotech names, where a single catalyst can override any technical setup. | ||
Short interest is elevated at 50% of float, which the engine judges as justified given the quality concerns — meaning a substantial bear thesis is already priced in that could pressure shares further if the clinical catalyst disappoints. Risk breakdown | Short interest should decline from 50% if the bear thesis proves overstated, rather than climbing further. | ↓Deteriorating |
| CounterExtremely high short interest creates real squeeze risk on any positive catalyst, which would argue against the bear case rather than for it. | ||
The stock has already run 19.9% past its V8 analyst-target level, leaving upside_pct negative and the risk/reward skewed unfavorably at the current price despite the sub-floor quality. Estimated upside | The asymmetry ratio should recover above 1.5, via either a pullback or a target upgrade, before this becomes an attractive entry. | →Stable |
| CounterA single strong catalyst, such as positive trial data, could justify a target upgrade large enough to restore favorable asymmetry without any price decline. | ||
A recent cluster of 9 analyst actions detected in the news triggered a bullish news-boost gate, signaling meaningful sell-side attention to a near-term catalyst even as the broader engine remains cautious on the stock.
→StableEngine gate (passed)
- Expectation
- The analyst cluster should translate into upgraded price targets or coverage initiations that support the stock over the next few months.
CounterA cluster of analyst notes can just as easily reflect a wave of downgrades or cautious initiations tied to bad news, not necessarily a bullish catalyst.
Replimune's quality score sits below the engine's floor, driven by negative free cash flow and no competitive moat, meaning the investment case rests entirely on clinical catalysts rather than current fundamentals.
→StableQuality breakdown
- Expectation
- Cash burn should not accelerate and the company should maintain sufficient runway through its next major clinical readout.
CounterPersistent cash burn without a moat increases the odds of a dilutive capital raise if a clinical setback occurs, which would impair per-share value regardless of the science.
The V9 momentum gate failed (3.8 versus the 4.5 threshold) even as RSI reads overbought at 79, an inconsistency suggesting the recent bounce lacks the broader technical support (falling on-balance volume) needed to sustain a rally.
→StableEngine gate (failed)
- Expectation
- Momentum should either clear the 4.5 threshold on renewed volume accumulation or the RSI-driven bounce should fade without new highs.
CounterMomentum gates calibrated for typical equities may not translate well to binary biotech names, where a single catalyst can override any technical setup.
Short interest is elevated at 50% of float, which the engine judges as justified given the quality concerns — meaning a substantial bear thesis is already priced in that could pressure shares further if the clinical catalyst disappoints.
↓DeterioratingRisk breakdown
- Expectation
- Short interest should decline from 50% if the bear thesis proves overstated, rather than climbing further.
CounterExtremely high short interest creates real squeeze risk on any positive catalyst, which would argue against the bear case rather than for it.
The stock has already run 19.9% past its V8 analyst-target level, leaving upside_pct negative and the risk/reward skewed unfavorably at the current price despite the sub-floor quality.
→StableEstimated upside
- Expectation
- The asymmetry ratio should recover above 1.5, via either a pullback or a target upgrade, before this becomes an attractive entry.
CounterA single strong catalyst, such as positive trial data, could justify a target upgrade large enough to restore favorable asymmetry without any price decline.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.8 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.7 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.6 |
| Price target | 8.6 |
| erm sentiment | 6.4 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 30%
Insider
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 4.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $32,093,799 (2.228% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.1 |
| support resistance | 3.2 |
| 52w position | 8.4 |
Risk (lower is worse)
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 7.3 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 7.6 |
| debt equity | 4.9 |
- ▸High short interest justified: 43%
- ▸Elevated put/call: 2.07
- ▸High IV: 91%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 8.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 1.7 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:61d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.4<4.5
- ASYMMETRY:0.8<1.5@spot
Warning (0)
none
Reward-to-Risk
0.85
Upside
+12.8%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 53 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.4<4.5 outcome against Insider at 7.5 and asymmetric R:R of 0.85.
The strongest dimensions are Insider at 7.5, Sentiment at 7.2, and Value at 6.0; the weakest are Quality at 1.5, Peer rank at 2.7, and Risk (lower is worse) at 2.8. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 0.85 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Cluster Catalyst
Trip ifThe average analyst price target is cut by more than 20% within 3 months of the cluster.
- P2Quality Below Floor Cash Burn
Trip ifThe company announces a dilutive equity raise that exceeds 15% of shares outstanding.
- P3Momentum Gate Failure
Trip ifMomentum score falls below 3.0 from the current 3.8 within the next month.
- P4Elevated Short Interest
Trip ifShort interest rises above 60% of float from the current 50%.
- P5Target Already Reached
Trip ifAsymmetry ratio stays below -1.0 for 2 consecutive months.